The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including ...

Bristol Myers Squibb (BMS), a leading biopharmaceutical company with a dominant position in immuno-oncology, held a press conference in Cyprus on April 29, 2025, where eminent pathologists-oncologists ...

Global and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is ...

JediCare Medical completes first-in-human feasibility study of world's first-of-its-kind pulmonary nodule percutaneous sphere resection: Shanghai Friday, May 2, 2025, 18:00 Hrs [I ...